Empowering Precision Medicine: Tubulis GmbH Secures $138.8 Million in Series B Funding to Revolutionize Protein-Drug Conjugates

Tubulis GmbH is thrilled to announce a remarkable achievement in its journey towards revolutionizing targeted therapies: the company has successfully raised a staggering €138.8 million in its latest funding round. This significant infusion of capital will propel Tubulis in its mission to generate uniquely matched protein-drug conjugates through the innovative integration of proprietary technologies and disease-specific biology. By focusing on the advancement of antibody drug conjugates (ADCs), Tubulis is set to usher in a new era in biopharmaceuticals, with a commitment to improving therapeutic outcomes for patients suffering from a range of diseases. The funding will not only bolster Tubulis’ discovery capabilities but also enhance its potential to tackle development challenges faced by partners across the industry. The team is motivated by the limitless possibilities that lie ahead as they work to create better and more effective conjugates, free from the limitations of any single indication. With this funding, Tubulis aims to expand its platform, enhance collaborations, and accelerate the clinical development of its promising candidates, ultimately paving the way for breakthroughs in medical treatments. As the landscape of drug discovery continues to evolve, Tubulis remains dedicated to its mission of delivering impactful therapies that address unmet medical needs and improve patient lives worldwide.